Today: 11 June 2026
Direct Digital Holdings stock price jumps 71% in premarket as DRCT rally puts Nasdaq deadline back in focus
23 January 2026
1 min read

Direct Digital Holdings stock price jumps 71% in premarket as DRCT rally puts Nasdaq deadline back in focus

New York, Jan 23, 2026, 05:41 ET — Premarket

  • DRCT surged 71% in premarket trading after climbing nearly 30% on Thursday
  • Nasdaq’s bid-price deadline on Jan. 30 maintains the threat of delisting
  • The January reverse stock split cut the Class A share count, reducing supply

Shares of Direct Digital Holdings, Inc. surged 71% to $3.95 in premarket action by 5:31 a.m. ET Friday, following a 29.8% gain to $2.31 at Thursday’s close. During regular trading, the stock fluctuated between $1.79 and $2.54, with volume spiking to roughly 11.8 million shares.

The sudden move is significant as the Nasdaq clock keeps ticking. Direct Digital must regain compliance with the exchange’s $1 minimum bid-price rule by Jan. 30, according to a filing. The rule demands the stock close at or above $1 for at least 10 straight business days.

The company attempted to recalibrate its share structure earlier this month with a 55-for-1 reverse stock split, effectively boosting the price per share. CEO Mark Walker described the move as an “important next step,” emphasizing the Nasdaq listing as “a key asset.” Following the split, Class A shares were expected to shrink from roughly 68.9 million to around 1.3 million, according to the company. PR Newswire

A separate filing this month brought another potential overhang into focus: shareholders gave the green light to issuing up to 100 million Class A shares through an equity reserve facility with New Circle Principle Investments LLC, plus roughly 41.8 million shares linked to a settlement. Equity reserve facilities, or equity lines, let companies drip stock into the market gradually.

The jump stood out, even as ad-tech stocks generally edged higher. Early trading showed Trade Desk, Magnite, and PubMatic each gaining roughly 4% to 5%.

Direct Digital operates its ad tech platform via Colossus SSP and Orange 142, but Friday’s early moves seemed driven more by structure than underlying fundamentals. The reverse split left far fewer shares available, so even small trades can send the price swinging sharply in either direction.

Premarket moves often amplify volatility, particularly with small caps, and the stock must meet Nasdaq’s criteria by month’s end. A drop back toward $1 would heighten delisting risks and put pressure on demand amid the threat of fresh share issuance.

Traders on Friday will be watching to see if the early rally sticks after markets open at 9:30 a.m. ET — and if Nasdaq delivers a compliance notice before the Jan. 30 cutoff. With no events scheduled on the company’s investor calendar, the listing decision looms as the next major trigger.

Stock Market Today

  • Live Cattle Futures Edge Higher Amid Mixed USDA Beef Prices
    June 11, 2026, 10:54 AM EDT. Live cattle futures rose by $1.45 to $1.60 across most front months on Wednesday, with December delivery slightly down. Feeder cattle futures gained $2.40 to $2.90 by midday. Open interest increased by 1,293 contracts. Managed money trimmed net long positions in live cattle futures and options by 7,083 contracts, totaling 101,265, while feeder cattle spec funds reduced holdings by 470 contracts. USDA reported a decline in wholesale boxed beef prices, with Choice boxes down $1.68 to $359.36 and Select down $3.15 to $344.88. Federally inspected cattle slaughter rose to an estimated 123,000 head Wednesday, exceeding last week but falling short of last year. The mixed data signals ongoing volatility in cattle markets as traders assess supply and demand factors.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap
Previous Story

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing
Next Story

CRISPR Therapeutics stock in focus as shares cool premarket after 11% surge and CEO sale filing

Go toTop